|
|
News Breaks | | | | April 2, 2012 | | 16:15 EDT |  | GRPN, WG, THRX, GSK, YPF, KERX, AVP | On The Fly: Closing Wrap
Stocks on Wall Street were higher after manufacturing reports in the U.S. and China indicated expansion. Stock futures traded below fair value for most of the pre-market trading session leading to a lower open for the broader market. The weakness was attributed to a high unemployment reading and a lackluster PMI report out of Europe. The market reversed its course and moved into positive territory following the slightly better than expected ISM manufacturing report here in the U.S. Once in positive territory the market moved quickly, but its advance stalled at a resistance level for the S&P. The move broadened out with the Nasdaq ending the day as the leading major index... ECONOMIC EVENTS: Domestically, the ISM manufacturing reading of 53.4 exceeded expectations for a 53.0 reading. Construction spending in February was down 1.1%, versus the expected increase of 0.6%. Internationally, an official reading of China's PMI rose to 53.1 while Markit's Eurozone manufacturing PMI fell to 47.7... MARKET NEWS: Avon Products (AVP) rejected the increased bid of $23.25 per share from fragrance-maker Coty. Avon shares rose $3.34, or 17.25%, to $22.70 following the announcement of the sweetened offer though Coty said it will not go hostile with its buyout plan... Groupon (GRPN) shares slid almost 17%, to $15.27, after the company announced weakness in its internal controls and revised its Q4 results lower... MAJOR MOVERS: Among the notable gainers were Willbros Group (WG), up 69c, or 21.30%, to $3.93, after its Q4 revenues beat expectations, and Theravance (THRX), up $3.79, or 19.44%, to $23.29, after GlaxoSmithKline (GSK) moved to raise its stake in the company to 26.8% with the purchase of 10M shares. Noteworthy losers included YPF SA (YPF), down $4.40, or 15.49%, to $24.01, following a downgrade at Merrill Lynch and a report that Argentina's government will take control of the company, and Keryx Biopharmaceuticals (KERX), down $3.24, or 65.06%, to $1.74, after the company announced that a trial for its lead drug missed its primary endpoint... INDICES: The Dow gained 52.45, or 0.40%, to 13,264.49; the Nasdaq added 28.13, or 0.91%, to 3,119.70; and the S&P 500 rose 10.43, or 0.74%, to 1,418.90. | |
|
News For AVP;GRPN;WG;THRX;GSK;YPF;KERX From The Last 14 Days Check below for free stories on AVP;GRPN;WG;THRX;GSK;YPF;KERX the last two weeks. |
|
|
| May 21, 2013 | | 07:07 EDT |  | GSK, THRX | Theravance pullback on Elan bid a buying opportunity, says Piper Jaffray
 Subscribe for More Information | | | May 16, 2013 | | 11:27 EDT |  | THRX | Options with decreasing implied volatility: LNCO MBI OPK THRX SGMO
Subscribe for More Information | | | 10:09 EDT |  | GRPN | Groupon co-CEO thinks revenue can grow to $100B annually, BI reports
Groupon co-CEO Ted Leonsis told Business Insider he believes the company can eventually generate $100B of revenue per year, according to an interview published last night. Reference Link | | | 06:03 EDT | | YPF | YPF, Chevron agree to terms of Argentina shale investment, Reuters reports
Subscribe for More Information | | | May 15, 2013 | | 11:13 EDT | | GRPN, THRX | Options with decreasing implied volatility: MM GMCR GRPN THRX SGMO
Subscribe for More Information | | | 10:35 EDT |  | GRPN | Groupon, Zynga advance after hedge fund reports new stakes
Subscribe for More Information | | | 09:58 EDT | | GRPN | Jana Partners reports new stakes in Groupon, Zynga
Subscribe for More Information | | | May 14, 2013 | | 12:16 EDT | | THRX | Options with decreasing implied volatility: MM PANL DGIT VCLK THRX
Subscribe for More Information | | | 11:44 EDT | | GRPN | Options with decreasing implied volatility: GRPN MAKO GMCR EZCH SGMO
| | | 10:07 EDT | | GRPN | Groupon introduces Breadcrumb point-of-sale app for iPad
Subscribe for More Information | | | | 08:16 EDT | | THRX | Theravance price target raised to $48 from $38 at RW Baird
Subscribe for More Information | | | 07:24 EDT |  | GSK | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | 07:07 EDT | | THRX | Theravance price target raised to $54 from $44 at Stifel
Stifel thinks that Theravance's (THRX) royalty deal with Elan (ELN) demonstrates its ability to generate revenue that had not been reflected in its stock price. The firm expects Theravance to make similar deals in the future and it keeps a Buy rating on the stock. | | | May 13, 2013 | | 16:25 EDT | | GSK, THRX | On The Fly: Closing Wrap
Stocks on Wall Street were little changed from their opening levels as investors weighed the potential end of the Fed's quantitative easing program against a better than expected report on retail sales. The Wall Street Journal's Jon Hilsenrath suggested in a report over the weekend that the Federal Reserve has mapped a QE exit strategy. The report paired with the retail sales data left the market lacking conviction in either direction today, as the averages spent the majority of the session range-bound near the flatline. ECONOMIC EVENTS: In the U.S., retail sales rose 0.1% in April, which beat expectations for a 0.3% decline. Retail sales excluding autos, gas, and building materials rose 0.6%, which was also better than expected. Business inventories were flat in March, versus expectations for a 0.3% gain. In Asia, Chinese factory output grew 9.3% annually in April, which was up from 8.9% in March but still missed expectations for a 9.5% growth rate. COMPANY NEWS: The Supreme Court ruled unanimously that Monsanto's (MON) patented genetically altered soybeans are protected and that farmers cannot use them to create new seeds without paying the company... Dell's (DELL) special committee publicly asked for more information from Carl Icahn and Southeastern Asset Management about their proposed leveraged recapitalization. This request follows television interviews by Icahn last Friday in which he discussed his Dell proposal, as well as a weekend report in Barron's saying the Icahn and Southeastern plan could be a better deal for shareholders. MAJOR MOVERS: Among the notable gainers was Theravance (THRX), up $6.26, or 17.92%, to $41.20 after Elan Corporation (ELN) bought a stake in the potential future royalty payments from four respiratory programs partnered with GlaxoSmithKline (GSK) in exchange for $1B in cash. Also higher was Tesla (TSLA), which rose $11.04, or 14.38%, to $87.80 in its third straight double-digit percentage gain following a better-than-expected earnings report last week. Among the noteworthy losers was Barnes & Noble (BKS), down $2.21, or 9.48%, to $21.10 after the blog InsiderMonkey disputed a previous report about Microsoft's (MSFT) interest in the bookseller's NOOK assets. Also lower was JoS. A. Bank (JOSB), down $3.31, or 7.16%, to $42.90 after the company's first quarter earnings view came in below expectations. INDICES: The Dow was down 26.81, or 0.18%, to 15,091.68; the Nasdaq was up 2.21, or 0.06%, to 3,438.79; and the S&P 500 was nearly unchanged at 1,633.77. | | | 12:20 EDT | | GSK, THRX | On The Fly: Midday Wrap
Subscribe for More Information | | | 09:25 EDT | | THRX | On The Fly: Pre-market Movers
Subscribe for More Information | | | 05:44 EDT | | GSK, THRX | Elan provides additional information on Elan/Theravance agreement
Subscribe for More Information | | | 05:35 EDT | | THRX, GSK | Theravance, Elan enter into $1B royalty participation agreement
Subscribe for More Information | | | 05:31 EDT | | THRX | Theravance, Elan enter into $1B royalty participation agreement
| | | 05:26 EDT | | THRX | Theravance to host conference call
Subscribe for More Information | | |
|
|
|
|
|
|
